Zhang C. Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia". Haematologica; https://doi.org/10.3324/haematol.2026.301608 [Early view].